Verici Dx plc (LON:VRCI), a developer of advanced clinical diagnostics for organ transplant, has announced its unaudited interim results for the six months ended 30 June 2026.
Financial highlights
- Revenues of $1.8m (H1 2025: $1.9m; FY 2025: $3.7m)
Includes Tutivia testing revenues up 53%. 2025 includes $0.75m of licensing revenues from Thermo Fischer
| H1 2026 US$m | H1 2025 US$m | FY2025 US$m | |
| Tutivia testing | 1.77 | 1.16 | 2.86 |
| Licensing revenues | – | 0.75 | 0.81 |
| 1.77 | 1.91 | 3.66 |
- Adjusted EBITDA1 loss of $3.5m (H1 2025: loss of $2.8m; FY 2025: loss of $6.2m)
- $2.4m cash balance as at 30 June 2026 (31 December 2025: $3.3m)
- Net cash outflow from operating activities of $3.8m (H1 2025: $3.5m outflow; FY 2025: $8.3m outflow)
- Equity fundraise completed in June 2026 raising gross proceeds of £2.6m ($3.4m)
- Today the Company has announced separately that it is proposing a further equity fundraise to support the Company’s growth plans
Operational highlights
- Tutivia testing volumes continue to increase quarter-on-quarter at a steady growth rate with Q3 2026 on track for a 53% increase in orders year on year
- 32 transplant centres onboarded and ordering tests in H1 2026, with a further three onboarded since 30 June
- The 35 centres currently using TutiviaTM now represent 23% of annual kidney transplants in the US (based upon UNOS.org data)
- Average reimbursement rate of $2,300 per test being achieved
- Appointment of Keith Gilliard as Senior Sales Director
- Agreement with Blue Cross and Blue Shield (‘BCBS’) of Illinois for Tutivia™, with contracted pricing across multiple lines of business, giving in-network status for BCBS covered patients and providing access to open contract processes with other BCBS entities
- Protega™ granted an additional CPT® Proprietary Laboratory Analyses (‘PLA’) code by the American Medical Association (‘AMA’) which is fundamental for commercial reimbursement
1 Earnings before income tax, depreciation and amortisation, adjusted to exclude share-based payments
Commenting on Outlook, Sara Barrington, Chief Executive Officer of Verici Dx, said: “H1 2026 has been a positive and progressive period for Verici. We continue to increase the number of centres ordering Tutivia and pleasingly three of the recent centres have already moved to high recurring ordering. Our current team of four business development directors, led by our recently appointed Senior Sales Director, Keith Gilliard, have delivered excellent revenue growth in Tutivia in the period and I am confident that that momentum will continue into H2 2026 and beyond.”
Verici Dx plc has also announced its intention to undertake a proposed equity fundraising with institutional and other investors.
The Proposed Fundraise is being conducted by Singer Capital Markets and Oberon Investments as joint bookrunners and brokers to the Company.
The Company has elected to utilise AIM’s Capital Access Window in connection with the Proposed Fundraise. Accordingly, trading in the Company’s Ordinary Shares on AIM will enter a Capital Access Window with effect from 7.30 a.m. on 1 October 2026 and trading will remain paused until a further announcement is made regarding the outcome of the Proposed Fundraise.
The price at which the new Ordinary Shares will be issued and the final number of new Ordinary Shares to be issued pursuant to the Proposed Fundraise will be determined following completion of the bookbuild. The Company will announce the results of the Proposed Fundraise as soon as practicable following completion of the bookbuild.
Proposed Fundraising
As stated at the time, the fundraise in June 2026 has provided the Company with sufficient funding to expand the commercial team, targeted marketing expenditure and to provide further working capital. The Proposed Fundraise will enable the Company to maintain these growth plans. The Board has been greatly encouraged by the support expressed from certain key shareholders to date for the Proposed Fundraise and the Company will update Shareholders with further details shortly.
Capital Access Window
Following the changes to the AIM Rules for Companies which took effect on 5 August 2026, the Company has elected to utilise the Capital Access Window in connection with the Proposed Fundraise. The new provisions permit AIM companies undertaking an equity fundraising to request a temporary pause in trading while the transaction is being negotiated or marketed.
The Board believes that use of the Capital Access Window is appropriate in connection with the Proposed Fundraise to provide pricing stability while the bookbuild is undertaken and facilitates engagement with a broad range of potential investors.
This announcement does not constitute an offer of securities in any jurisdiction. The Proposed Fundraise, if implemented, will be the subject of further announcements, which will include the material terms and conditions of the Proposed Fundraise.
